发明名称 PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS
摘要 The invention provides a combination comprising an ancillary compound (e.g. one, two or more ancillary compounds) and a compound of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R<SUP>1</SUP> and NR<SUP>2</SUP>R<SUP>3</SUP> and a maximum chain length of 4 atoms extending between E and NR<SUP>2</SUP>R<SUP>3</SUP>, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR<SUP>2</SUP>R<SUP>3</SUP> group and provided that the oxo group when present is located at a carbon atom a with respect to the NR<SUP>2</SUP>R<SUP>3</SUP> group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R<SUP>1</SUP> is an aryl or heteroaryl group; and R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP> and R<SUP>5</SUP> are as defined in the claims. Also provided are patient packs, pharmaceutical kits and packs and compositions containing the combinations, methods for preparing the combinations and their use in combination therapy as anticancer agents.
申请公布号 WO2006136837(A3) 申请公布日期 2007.02.15
申请号 WO2006GB02297 申请日期 2006.06.21
申请人 ASTEX THERAPEUTICS LIMITED;THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL;CANCER RESEARCH TECHNOLOGY LIMITED;THOMPSON, NEIL, THOMAS;BOYLE, ROBERT, GEORGE;COLLINS, IAN;GARRETT, MICHELLE, DAWN;LYONS, JOHN, FRANCIS;THOMPSON, KYLA, MERRIOM 发明人 THOMPSON, NEIL, THOMAS;BOYLE, ROBERT, GEORGE;COLLINS, IAN;GARRETT, MICHELLE, DAWN;LYONS, JOHN, FRANCIS;THOMPSON, KYLA, MERRIOM
分类号 A61K31/415;A61K31/454;A61P35/00;A61P37/00 主分类号 A61K31/415
代理机构 代理人
主权项
地址